Antibiotic Interactions with Apixaban

Introduction to Safe and Problematic Antibiotics

The American Heart Association recommends that most commonly prescribed antibiotics are safe to use with apixaban, with the notable exception of certain strong CYP3A4 and P-gp inhibitors, although clarithromycin has been shown to be safe despite being a strong dual inhibitor 1
The European Respiratory Society notes that apixaban is metabolized through two key pathways, CYP3A4 enzyme metabolism and P-glycoprotein (P-gp) transport, which determine potential interactions with antibiotics 1
The European Respiratory Society also mentions that the BCRP transporter contributes to drug clearance, which is relevant when considering interactions with antibiotics 2

The American College of Cardiology recommends that penicillins, cephalosporins, fluoroquinolones, clarithromycin, azithromycin, doxycycline, and metronidazole can be used without dose adjustment or special concern when taking apixaban 1

The American Heart Association suggests that erythromycin, a moderate CYP3A4 inhibitor, may require closer monitoring for bleeding signs when used with apixaban 1
The American College of Cardiology notes that trimethoprim-sulfamethoxazole may have additive effects on renal function, requiring caution when used with apixaban 1

The American Heart Association warns that rifampin, a strong CYP3A4 inducer, significantly reduces apixaban levels, increasing thrombotic risk, and should be avoided 1
The European Respiratory Society notes that nafcillin, a CYP3A4 inducer, can also reduce apixaban levels over time 1

The American College of Cardiology recommends assessing creatinine clearance before prescribing any antibiotic with potential interaction, as impaired renal function amplifies drug-drug interactions with apixaban 3
The American Heart Association suggests monitoring patients with CrCl 30-50 mL/min more closely, as they face compounded bleeding risk with even moderate inhibitors 3
The European Respiratory Society notes that patients with age >75 years, weight <50 kg, or concurrent antiplatelet use are at higher risk of bleeding and should be monitored more closely 1, 3, 4

The American College of Cardiology recommends screening for concurrent antiplatelet or NSAID use and considering PPI prophylaxis when prescribing antibiotics to patients on apixaban 1
The American Heart Association suggests monitoring for bleeding signs throughout antibiotic therapy and 3-5 days after completion 3

The European Respiratory Society recommends considering switching to low molecular weight heparin during the antibiotic course if a problematic antibiotic like rifampin is necessary 2
The American College of Cardiology notes that edoxaban is minimally metabolized by CYP3A4 and represents a safer DOAC alternative with strong CYP3A4 modulators 2, 3